M&A / Deals Eli Lilly makes $7.8bn takeover play for Centessa PharmaphorumSleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.M&A / DealsRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) Pharmaphorum Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech. M&A / DealsRead full story Post navigation Previous: Merck strikes deal with antibody discovery startupNext: Biogen swoops on Apellis with $5.6bn offer Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
